LNTH News and Press, Lantheus Holdings Inc. From 11/05/20

The following slide deck was published by Lantheus Holdings, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Lantheus Holdings, Inc. 2020 Q3 - Results - Earnings Call Presentation

Lantheus (LNTH): Q3 Non-GAAP EPS of $0.04 beats by $0.10; GAAP EPS of -$0.10 beats by $0.07.Revenue of $88.54M (+3.2% Y/Y) misses by $3.42M.Press Release For further details see: Lantheus EPS beats by $0.10, misses on revenue

Worldwide revenue of $88.5 million for the third quarter 2020, representing an increase of 3.2% from the prior year period Net loss of $6.4 million for the third quarter 2020, compared to net income of $4.9 million in the prior year period GAAP diluted EPS of $(0.10)...

Lantheus (NASDAQ:LNTH) is scheduled to announce Q3 earnings results on Thursday, November 5th, before market open.The consensus EPS Estimate is -$0.06 (-121.4% Y/Y) and the consensus Revenue Estimate is $91.96M (+7.2% Y/Y).Over the last 2 years, LNTH has beaten EPS estimates 100% of the time ...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and th...

Lantheus Holdings (LNTH) will collaborate with privately held Haifa, Israel-based Insightec Ltd. to evaluate the use of LNTH's microbubbles, combined with Insightec's investigational MR-guided Focused Ultrasound (MRgFUS) platform, for the treatment of glioblastoma and neurodegenerative condit...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced a str...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc., and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnost...

Lantheus Holdings (LNTH), which merged with Progenics Pharmaceuticals (PGNX) in June, announces the filing of a U.S. marketing application seeking approval of PyL (18-F DCFPyL), a prostate-specific membrane antigen ((PSMA))-targeted positron emission tomography ((PET)) imaging agent for ...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents a...